N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease

A compound of formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• ring A is pyridinyl or phenyl;
• ring B is pyridinyl or phenyl;
• R1 and R2 combine to form a C3-6 cycloalkyl wherein said C3-6 cycloalkyl is optionally substituted with 1, 2 or 3 halogens;
• R3 is —O—R3′, —NH—R3′, phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, a 7 to 10 membered fused heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene, wherein said phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene is optionally substituted with 1 to 4 substituents each independently selected from halogen, CD3, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, pyridinyl and halo-substituted-C1-4alkoxy, or R3 is C1-4alkyl, CD3, C1-5alkoxy or C1-4alkenyl, wherein said C1-4alkyl, C1-4alkenyl or C1-4alkoxy is optionally substituted with 1 to 3 substituents each independently selected from halogen and an optionally substituted phenyl wherein said phenyl is substituted with halo-substituted-C1-2alkyl, methyl or 1, 2 or 3 halogens;
• R3′ is —C0-3alkyl-C3-8 cycloalkyl, or a fully or partially saturated —C9-10bicycloalkyl, wherein said —C0-3alkyl-C3-8 cycloalkyl or fully or partially saturated —C9-10bicycloalkyl is optionally substituted with C1-4alkyl;
• R4 is C1-4alkyl, C1-4alkoxy, CD3, halogen or halo-substituted-C1-4alkyl;
• R5 is —NR7R8 or R9;
• R6 is hydrogen or halogen;
• R7 is hydrogen, C1-6alkyl, C3-6 cycloalkyl, C4-7 heterocycloalkyl, wherein said C1-6alkyl, C3-6 cycloalkyl or C4-7 heterocycloalkyl is optionally substituted with 1 to 4 substituents each independently selected from deuterium, hydroxy, C1-4alkoxy, C1-4alkyl and C3-6 cycloalkyl;
• R8 is hydrogen or C1-4alkyl;
• R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, optionally substituted pyridinyl, NHR11, —C(O)—R13, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl or pyridinyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl, or R9 is perdeuterated morpholinyl, a 7 to 10 membered fused heterocycle or spirocyclic heterocycle optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, C3-6 cycloalkyl, phenyl, C4-6 heterocycle, NHR1, —S(O)2—R15, —C(O)—R13, —C(O)NHR11, C1-4alkyl-C(O)OR12, —C(O)C1-3alkyl-NHR11 and —C(O)O—R12, wherein said phenyl, C3-6 cycloalkyl and C4-6 heterocycle are optionally substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino, C1-4alkyl, halo-substituted-C1-4alkyl and hydroxy-substituted-C1-4alkyl;
• R11 is hydrogen, C1-4alkyl, —C(S)NH—R15, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
• R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
• R13 is C1-4alkyl, wherein said alkyl is optionally substituted with amino;
• R14 is hydrogen or C1-4alkyl;
• and
• R15 is C3-6 cycloalkyl, phenyl, tolyl or C1-4alkyl.